drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Chimeric anti-CD20 monoclonal antibody that mediates B-cell depletion via ADCC, complement-dependent cytotoxicity, and direct apoptosis.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes CD20+ cells via Fc-mediated ADCC, complement-dependent cytotoxicity, and direct induction of apoptosis.
drug_name
Rituximab
nct_id_drug_ref
NCT06158399